HK1087327A1 - Modified natriuretic compounds, conjugates, and uses thereof - Google Patents

Modified natriuretic compounds, conjugates, and uses thereof

Info

Publication number
HK1087327A1
HK1087327A1 HK06107556.5A HK06107556A HK1087327A1 HK 1087327 A1 HK1087327 A1 HK 1087327A1 HK 06107556 A HK06107556 A HK 06107556A HK 1087327 A1 HK1087327 A1 HK 1087327A1
Authority
HK
Hong Kong
Prior art keywords
conjugates
compounds
disclosed
natriuretic
modified
Prior art date
Application number
HK06107556.5A
Other languages
English (en)
Inventor
Kenneth D James
Balasingam Radhakrishnan
Navdeep B Malkar
Mark A Miller
Nnochiri N Ekwuribe
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of HK1087327A1 publication Critical patent/HK1087327A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)
HK06107556.5A 2002-11-26 2006-07-04 Modified natriuretic compounds, conjugates, and uses thereof HK1087327A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42915102P 2002-11-26 2002-11-26
PCT/US2003/037996 WO2004047871A2 (en) 2002-11-26 2003-11-12 Modified naturetic compounds, conjugates, and uses thereof

Publications (1)

Publication Number Publication Date
HK1087327A1 true HK1087327A1 (en) 2006-10-13

Family

ID=32393512

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06107556.5A HK1087327A1 (en) 2002-11-26 2006-07-04 Modified natriuretic compounds, conjugates, and uses thereof

Country Status (13)

Country Link
US (1) US7662773B2 (xx)
EP (1) EP1569683B1 (xx)
JP (1) JP2006515579A (xx)
CN (1) CN100558398C (xx)
AT (1) ATE459370T1 (xx)
AU (2) AU2003297583B2 (xx)
BR (1) BR0316560A (xx)
CA (1) CA2504287A1 (xx)
DE (1) DE60331584D1 (xx)
HK (1) HK1087327A1 (xx)
PL (1) PL377813A1 (xx)
SG (1) SG159387A1 (xx)
WO (1) WO2004047871A2 (xx)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
US7655772B2 (en) 2002-09-06 2010-02-02 University Of South Florida Materials and methods for treatment of allergic diseases
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
WO2004022579A2 (en) * 2002-09-06 2004-03-18 University Of South Florida Cellular delivery of natriuretic peptides
US20050272650A1 (en) * 2004-02-17 2005-12-08 Mohapatra Shyam S Materials and methods for treatment of inflammatory and cell proliferation disorders
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
AU2003297583B2 (en) 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
KR101152470B1 (ko) 2003-08-13 2012-06-01 바이오콘 리미티드 치료제용 마이크로-입자 지방산 염 고형 투약 제형
ES2365023T3 (es) 2004-04-21 2011-09-20 Enobia Pharma Inc. Conjugados de administración ósea y método de uso de los mismos para dirigir proteínas a hueso.
DE602005026014D1 (de) 2004-07-15 2011-03-03 Univ Queensland Proteinartige verbindungen und anwendungen davon
WO2006076471A2 (en) * 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
US7300494B2 (en) * 2005-02-24 2007-11-27 Hamilton Sundstrand Corporation On-board inert gas generation system with compressor surge protection
ES2554713T3 (es) * 2005-04-07 2015-12-22 Cardiorentis Ag Uso de un péptido natriurético para tratar insuficiencia cardiaca
DK1922350T3 (en) 2005-07-29 2015-03-09 Nektar Therapeutics Methods for preparing polymerreagenser
US7803901B2 (en) * 2005-09-16 2010-09-28 Mayo Foundation For Medical Education And Research Polypeptides with natriuresis activity
WO2007047834A2 (en) * 2005-10-18 2007-04-26 Biocon Limited Oral peptide conjugates for metabolic diseases
WO2007115175A2 (en) 2006-03-30 2007-10-11 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
US7795221B2 (en) 2006-03-30 2010-09-14 Palatin Technologies, Inc. Linear natriuretic peptide constructs
CA2656990A1 (en) * 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
DK2037948T3 (en) 2006-05-30 2016-08-01 Mayo Foundation Detection and treatment of dementia
JP5123936B2 (ja) 2006-05-30 2013-01-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 認知症の検出および治療
US8486412B2 (en) 2006-06-01 2013-07-16 Mayo Foundation For Medical Education And Research Immunity to folate receptors
US8008261B2 (en) 2006-08-04 2011-08-30 Mayo Foundation For Medical Education And Research Methods of reducing trail-induced apoptosis by trail isoforms
JP2010502231A (ja) 2006-09-08 2010-01-28 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 血管拡張作用を欠く水利尿およびナトリウム利尿ポリペプチド
RU2459624C2 (ru) 2007-04-12 2012-08-27 Риджентс Оф Дзе Юниверсити Оф Миннесота Защитные композиции от ишемии/реперфузии и способы применения
KR20080098216A (ko) * 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
AR069409A1 (es) 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
WO2009156481A1 (en) * 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
EP2350118B1 (en) * 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
EP2334335A1 (en) 2008-09-19 2011-06-22 Nektar Therapeutics Polymer conjugates of cd-np peptides
HUE057174T2 (hu) 2009-05-20 2022-04-28 Biomarin Pharm Inc A C-típusú nátriuretikus peptid variánsai
WO2011005939A2 (en) 2009-07-09 2011-01-13 Mayo Foundation For Medical Education And Research Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
DK2457581T3 (da) 2009-07-23 2014-03-31 Igisu Co Ltd Sammensætning omfattende CNP eller BNP for et udvendigt præparat til hud til behandling af dermatitis
SG184860A1 (en) 2010-04-27 2012-11-29 Agency Science Tech & Res Eif4e binding peptides
WO2012013597A1 (de) * 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
EP2678002A2 (en) 2011-02-25 2014-01-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
WO2012118042A1 (ja) 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
US9233143B2 (en) 2011-08-19 2016-01-12 National Cerebral And Cardiovascular Center Medicinal agent for preventing exacerbation of malignant tumor, comprising combination of natriuretic peptide receptor GC-A and GC-B agonists
CN107090028A (zh) 2011-08-30 2017-08-25 梅约医学教育与研究基金会 利钠多肽
WO2013033675A1 (en) 2011-09-02 2013-03-07 Medtronic, Inc. Chimeric natriuretic peptide compositions and methods of preparation
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US20150315259A1 (en) * 2012-03-19 2015-11-05 Madeleine Phamaceuticals Pty Ltd Method of producing a recombinant peptide
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
TW201442721A (zh) * 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
US10449236B2 (en) 2014-12-05 2019-10-22 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
CN107709352A (zh) 2015-05-29 2018-02-16 Igisu株式会社 环肽以及含有该环肽的药物、外用剂和化妆品
US11352612B2 (en) 2015-08-17 2022-06-07 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
AU2017205268B2 (en) * 2016-01-08 2022-02-17 Ascendis Pharma Growth Disorders A/S CNP prodrugs with large carrier moieties
KR20180100624A (ko) 2016-01-08 2018-09-11 아센디스 파마 그로우쓰 디스오더스 에이/에스 증가된 nep 안정성을 갖는 제어 방출성 cnp 작용제
US11389511B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
CN115177720A (zh) * 2016-01-08 2022-10-14 阿森迪斯药物生长障碍股份有限公司 具有低npr-c结合的控制释放cnp激动剂
AU2017205693B2 (en) * 2016-01-08 2022-03-31 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low initial NPR-B activity
EP3400019B1 (en) * 2016-01-08 2022-09-28 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
CA3019726A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
HRP20230385T1 (hr) 2016-09-29 2023-06-23 Ascendis Pharma Growth Disorders A/S Kombinirana terapija sa cnp agonistima s kontroliranim oslobađanjem
WO2018089601A1 (en) 2016-11-09 2018-05-17 Mayo Foundation For Medical Education And Research Manp analogues
CA3056433A1 (en) * 2017-03-22 2018-09-27 Pharmain Corporation Npra agonists, compositions, and uses thereof
CN110719786A (zh) 2017-03-31 2020-01-21 阿雷克森制药公司 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
JP2020532565A (ja) 2017-09-05 2020-11-12 トルク セラピューティクス， インコーポレイテッド 可逆性リンカーおよびその使用
JP7216332B2 (ja) 2018-03-20 2023-02-01 日油株式会社 分岐型単分散ポリエチレングリコール、中間体およびその製造方法
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
KR102022118B1 (ko) * 2019-01-07 2019-09-18 주식회사 아스트로젠 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물
CN110278941B (zh) * 2019-07-11 2021-05-28 西安国际医学中心有限公司 一种含有钠尿肽的离体心脏保护液
CN111848776B (zh) * 2020-08-31 2022-03-18 江苏璟泽生物医药有限公司 聚乙二醇修饰的rhBNP及其制备方法
CN111978390B (zh) * 2020-08-31 2022-10-14 上海景泽生物技术有限公司 聚乙二醇修饰的rhBNP及其用途
CA3173631A1 (en) 2021-02-12 2022-08-18 Walter C. Voegtli Alkaline phosphatase polypeptides and methods of use thereof
WO2023039392A1 (en) * 2021-09-07 2023-03-16 Mayo Foundation For Medical Education And Research Methods and materials for determining pgc target dosage
CN114316020A (zh) * 2021-12-28 2022-04-12 南京岚煜生物科技有限公司 一种bnp重组蛋白及其制备方法和应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044196A (en) * 1972-03-30 1977-08-23 Bayer Aktiengesellschaft Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4489065A (en) * 1981-07-02 1984-12-18 Valcor Scientific Ltd. Chondroitin drug Complexes
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4569794A (en) * 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5037741A (en) * 1986-08-18 1991-08-06 The Coca Cola Company Enzymatic method for the synthesis and separation of peptides
JP2544929B2 (ja) * 1987-06-17 1996-10-16 第一化学薬品 株式会社 新規生理活性ペプチド
US5114923A (en) 1988-05-31 1992-05-19 California Biotechnology Inc. Recombinant techniques for production of novel natriuretic and vasodilator peptides
CA1339210C (en) 1988-05-31 1997-08-05 John Lewicki Recombinant techniques for production of novel natriuretic and vasodilator peptides
JP2539665B2 (ja) * 1988-06-20 1996-10-02 日本臓器製薬株式会社 神経疾患治療剤
JP2561513B2 (ja) 1988-07-04 1996-12-11 塩野義製薬株式会社 γ−ＡＮＰを認識するモノクローナル抗体
JPH0720857B2 (ja) 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
IT1229514B (it) 1989-01-30 1991-09-03 Farmhispania S A A Montme Glicoconiugati anfifilici sintetici per impiego neurologico.
US20020086843A1 (en) 1989-03-01 2002-07-04 Daiichi Pure Chemicals Co., Ltd. Physiologically active polypeptide and DNA
EP0385476B2 (en) 1989-03-01 1999-09-22 SHIONOGI & CO., LTD. Physiologically active polypeptide and DNA
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
ATE170192T1 (de) 1989-06-23 1998-09-15 Genentech Inc Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
US5108568A (en) * 1989-07-07 1992-04-28 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Controlled method of reducing electrophoretic mobility of macromolecules, particles or cells
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
SE8904407L (sv) 1989-12-29 1991-06-30 Qingpingfeng Medikament foer behandling av hjaertsvikt
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5202239A (en) 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
US5853746A (en) 1991-01-31 1998-12-29 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier
ATE253639T1 (de) 1991-08-19 2003-11-15 Daiichi Suntory Pharma Co Ltd Verfahren zur herstellung von peptiden
JP2665850B2 (ja) 1991-11-14 1997-10-22 塩野義製薬株式会社 ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
CA2188143A1 (en) 1992-12-09 1995-11-02 Wolf-Georg Forssmann Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereof
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5512459A (en) * 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
DE69426986T2 (de) 1993-08-28 2001-10-25 The University Of Sheffield, Sheffield Behandlung von laminitis
US6525022B1 (en) 1993-11-12 2003-02-25 Genentech, Inc. Receptor specific atrial natriuretic peptides
US6037145A (en) 1994-09-07 2000-03-14 Suntory Limited Process for production of protein
ATE180058T1 (de) * 1994-12-09 1999-05-15 Shionogi & Co Sandwich-immunotestverfahren für n-peptide
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
AU730969B2 (en) 1995-10-19 2001-03-22 University Of Washington Discrete-length polyethylene glycols
DK2292662T3 (da) * 1996-03-04 2014-05-05 Scios Inc ASSAY OG REAGENSER TIL KVANTIFICERING AF hBNP
AU734312B2 (en) 1996-03-22 2001-06-07 General Hospital Corporation, The Administration of polypeptide growth factors following central nervous system ischemia or trauma
US6028055A (en) 1996-10-22 2000-02-22 Genetech, Inc. Receptor selective BNP
ZA979060B (en) 1996-10-22 1999-04-09 Genentech Inc Receptor selective BNP
WO1998045329A1 (en) 1997-04-04 1998-10-15 Novo Nordisk A/S Natriuretic peptide derivatives
US20040005669A1 (en) * 1997-08-07 2004-01-08 Stefan Stahl Recombinant expression of insulin C-peptide
GB9716790D0 (en) 1997-08-07 1997-10-15 Creative Peptides Sweden Ab Recombinant DNA molecules comprising multimeric copies of a gene sequence and expression thereof
US6013630A (en) 1997-08-21 2000-01-11 Curagen Corporation Atrial natriuretic factor mutants and ischemic stroke
CA2306751C (en) 1997-10-24 2006-12-12 Shionogi & Co., Ltd. Method for inhibiting degradation of natriuretic peptides and improved method for measuring natgriuretic peptides with the use of the same
US6495514B1 (en) * 1998-01-21 2002-12-17 Mercer University Method for reducing inflammation and inducing an analgesic effect and compounds thereof
CA2321026A1 (en) * 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6117644A (en) * 1998-06-04 2000-09-12 Ottawa Heart Institute Research Corporation Predicting and detecting cardiac allograft rejection
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
SE9802946D0 (sv) 1998-09-02 1998-09-02 Europrofil Ab Förfarande och listarrangemang för att täcka skarvar eller skapa övergångar i samband med ytbeläggningar
JP3799465B2 (ja) * 1998-09-28 2006-07-19 参天製薬株式会社 ナトリウム利尿ペプチドを有効成分とする涙液分泌促進または角結膜障害治療用点眼剤
WO2000043034A2 (en) 1999-01-26 2000-07-27 Eli Lilly And Company Monodisperse hexameric acylated insulin analog formulations
DE60026300T2 (de) * 1999-05-17 2006-11-16 Conjuchem, Inc., Montreal Schutz endogener, therapeutisch aktiver peptide vor peptidaseaktivität durch konjugation an blutbestandteile
WO2000071576A2 (en) 1999-05-24 2000-11-30 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
US6610043B1 (en) * 1999-08-23 2003-08-26 Bistech, Inc. Tissue volume reduction
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6541508B2 (en) * 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
US7127290B2 (en) 1999-10-01 2006-10-24 Cardiac Pacemakers, Inc. Cardiac rhythm management systems and methods predicting congestive heart failure status
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
JP4237375B2 (ja) * 2000-03-31 2009-03-11 アスビオファーマ株式会社 虚血性疾患の処置又は予防に用いる医薬組成物
DE60140491D1 (de) * 2000-08-29 2009-12-24 Biocon Ltd Verwendung einer pharmazeutischen Zusammensetzung mit einem Para-Aminophenylessigsäurederivat für die Behandlung von entzündlichen Erkrankungen des Magen-Darmtrakts
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
US20030219734A1 (en) * 2001-04-13 2003-11-27 Biosite Incorporated Polypeptides related to natriuretic peptides and methods of their identification and use
FR2823993B1 (fr) * 2001-04-27 2003-06-20 Rhodia Chimie Sa Dispersion colloidale aqueuse stable, son procede de preparation
EP1666881B1 (en) * 2001-05-04 2010-02-17 Biosite Incorporated Diagnostic markers of acute coronary syndromes and methods of use thereof
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6737913B2 (en) * 2001-06-15 2004-05-18 Silicon Laboratories, Inc. Differential mode circuitry and method of calibrating same without matched external current sources
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
EP1430082B1 (en) 2001-09-07 2009-10-28 Biocon Limited Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
AU2003214210A1 (en) * 2002-03-18 2003-10-08 Scios Inc. Treatment of congestive heart failure with natriuretic peptide and a diuretic
EP1530588A2 (en) 2002-07-31 2005-05-18 Conjuchem, Inc. Long lasting natriuretic peptide derivatives
US20040152769A1 (en) 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
AU2003297583B2 (en) 2002-11-26 2010-01-14 Biocon, Ltd Modified naturetic compounds, conjugates, and uses thereof
US20060198819A1 (en) * 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest

Also Published As

Publication number Publication date
SG159387A1 (en) 2010-03-30
WO2004047871A3 (en) 2005-03-17
CA2504287A1 (en) 2004-06-10
DE60331584D1 (de) 2010-04-15
BR0316560A (pt) 2005-10-04
ATE459370T1 (de) 2010-03-15
CN100558398C (zh) 2009-11-11
US20040203081A1 (en) 2004-10-14
EP1569683B1 (en) 2010-03-03
WO2004047871A2 (en) 2004-06-10
JP2006515579A (ja) 2006-06-01
AU2003297583B2 (en) 2010-01-14
CN1741814A (zh) 2006-03-01
AU2003297583A1 (en) 2004-06-18
EP1569683A2 (en) 2005-09-07
PL377813A1 (pl) 2006-02-20
AU2010201455A1 (en) 2010-05-06
US7662773B2 (en) 2010-02-16

Similar Documents

Publication Publication Date Title
HK1087327A1 (en) Modified natriuretic compounds, conjugates, and uses thereof
WO2005116655A3 (en) Natriuretic compounds, conjugates, and uses thereof
WO2006076471A3 (en) Bnp conjugates and methods of use
US20180016319A1 (en) Acylated Glucagon Analogues
WO2003103572A3 (en) MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1)
WO2005058958A3 (en) Novel glp-1 analogues linked to albumin-like agents
KR20090098843A (ko) 신규 화합물 및 식습관에 대한 이의 효과
JP6383667B2 (ja) 生理活性ポリペプチド複合体の製造のための改善工程
BRPI1014416B1 (pt) Nova variante de exendina e conjugado desta
RU2014129893A (ru) Фармацевтическая композиция и способ лечения связанных с гормоном роста заболеваний у человека
EP3495384A1 (en) Acylated derivative of human insulin or analogue thereof
RU2009105696A (ru) N-концевое полисиалилирование
RU2012109553A (ru) Модифицированные вазоактивные интестинальные пептиды
WO2009158704A3 (en) Therapeutic agents comprising elastin-like peptides
RU2015142992A (ru) Сайт-специфическая конъюгация антитело-лекарственное средство посредством гликоинженерии
JP2008500375A5 (xx)
IE841890L (en) Treatment of diabetes mellitus
EP2107069A3 (en) Novel insulin derivatives
ZA200202520B (en) C-peptide for the improved production of insulin and insulin analogues.
KR102185311B1 (ko) 인슐린 위치 특이적 결합체
MXPA05004993A (es) Conjugados de hormona del crecimiento humana modificados quimicamente.
EP2275439A3 (en) Novel insulin derivatives
TW200502251A (en) Natriuretic compound conjugates, conjugates, and uses thereof
CA2529449A1 (en) Pharmaceutical composition comprising cyclic somatostatin analogues
CA2294996A1 (en) Angiotensin derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131112